Future Directions in HR-Positive, HER2-Negative Early Breast Cancer

Looking ahead, the faculty discuss unanswered questions and future data needs in the adjuvant treatment of HR-positive, HER2-negative early breast cancer. Topics include anticipated overall survival results from NATALEE, the role of dose intensity and treatment duration, and emerging considerations for patients who recur after receiving adjuvant CDK4/6 inhibitors. The conversation also highlights how ongoing research may refine patient selection and sequencing strategies over time. These forward-looking insights reinforce that adjuvant CDK4/6 therapy is an evolving field with continued implications for long-term patient management.